BioRegeneration Technologies Inc, is addressing a treatment gap for patients suffering from Osteoarthritis (OA). While OA is the most common joint disorder affecting more than 20 million people in the United States, a large group of patients are left to manage their symptoms, such as pain and limited mobility, while waiting for the disease to progress to a more severe level. Instead of waiting for disease progression and later addressing it through complete joint replacement using metals or plastics, BioRegeneration Technologiesâ treatment approach holds the promise of reversing the degeneration of tissue caused by OA. The firms proprietary product, Regen-C, is placed in a damaged joint surface and its porous material absorbs nutrients from surrounding areas to facilitate the body's natural healing processes, repair the injured joint and prevent osteoarthritis. Regen-C mimics the natural transition between bone and cartilage. It is the only technology of its kind that has this continuous transition. With current treatments, patients get temporary pain relief and scar tissue forms, but eventually it breaks down. Currently, there is no long-term durability, leaving a patient with either partial or total joint replacement.
